These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 1929760)

  • 41. Psychotogenic drug use and neuroleptic response.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Schizophr Bull; 1990; 16(1):81-5. PubMed ID: 1970670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
    Breier A; Davis OR; Buchanan RW; Moricle LA; Munson RC
    Arch Gen Psychiatry; 1993 Jul; 50(7):541-50. PubMed ID: 8317948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measurement of plasma homovanillic acid concentrations in schizophrenic patients.
    Kaminski R; Powchick P; Warne PA; Goldstein M; McQueeney RT; Davidson M
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(3):271-87. PubMed ID: 2193315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
    Csernansky JG; Newcomer JW; Jackson K; Lombrozo L; Faull KF; Zipursky R; Pfefferbaum A; Faustman WO
    Psychopharmacology (Berl); 1994 Nov; 116(3):291-6. PubMed ID: 7534423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
    Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK
    Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia.
    Thibaut F; Ribeyre JM; Dourmap N; Ménard JF; Dollfus S; Petit M
    Biol Psychiatry; 1998 Jan; 43(1):24-30. PubMed ID: 9442341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
    Kuhs H; Folkerts H
    Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI; Sharma RP; Janicak PG; Davis JM
    Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Schizophrenia: gender, family risk, and plasma homovanillic acid.
    Dávila R; Zumárraga M; González-Torres MA; Andía I; Zamalloa MI; Basterreche E; Guimón J; Friedhoff AJ
    Am J Med Genet; 1995 Apr; 60(2):154-6. PubMed ID: 7485251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.
    Miller AL; Maas JW; Contreras S; Seleshi E; True JE; Bowden C; Castiglioni J
    Biol Psychiatry; 1993 Aug; 34(3):178-87. PubMed ID: 8104509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
    Szymanski S; Lieberman JA; Alvir JM; Mayerhoff D; Loebel A; Geisler S; Chakos M; Koreen A; Jody D; Kane J
    Am J Psychiatry; 1995 May; 152(5):698-703. PubMed ID: 7726309
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine.
    Yamada K; Kanba S; Wang ZC; Suzuki E; Fang YY; Yan HG; Nibuya M; Yagi G; Asai M
    Psychiatry Clin Neurosci; 1996 Oct; 50(5):291-4. PubMed ID: 9201793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
    J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Memory and plasma HVA changes in schizophrenia: are they episode markers?
    Gilbertson MW; Yao JK; van Kammen DP
    Biol Psychiatry; 1994 Feb; 35(3):203-6. PubMed ID: 8173021
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.